Facebook
Twitter
LinkedIn
ForwardAUAUniversity Podcast Series: Episode No. 165
DEI In Urology: Financial Toxicity as Drugs Move Earlier into Treatment Paradigm
Financial Toxicity as Drugs Move Earlier into Treatment Paradigm and How This Relates to Disparities in Treatment Patterns
CME Available: auau.auanet.org/node/35729
Moderator: Jay D. Raman, MD, FACS
Co-Hosts: Sarah Psutka, MD, MS
LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:
1. Define the magnitude of financial toxicity/economic implications across GU malignancies currently.
2. Forecast the potential changes/increases in financial burden associated with moving systemic therapies earlier in treatment paradigms for patients with GU malignancies.
ACKNOWLEDGEMENTS
Support provided by independent educational grants from:
Astellas
AstraZeneca
Bayer
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Merck & Co., Inc.
Pfizer, Inc.